NCT05223660View on ClinicalTrials.gov

A Phase I Pharmacokinetics Study for KT07 Capsule

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 7, 2022

Primary Completion Date

July 20, 2022

Study Completion Date

September 6, 2022

Conditions
Healthy Adult SubjectsPharmacokineticsSafety and Tolerability
Interventions
DRUG

Low dose KT07

A single dose of 4 capsules, followed by multiple doses on Days 8-12

DRUG

High dose KT07

A single dose of 6 capsules, followed by multiple doses on Days 8-12

DRUG

Low dose Placebo

A single dose of 4 capsules, followed by multiple doses on Days 8-12

DRUG

High dose Placebo

A single dose of 6 capsules, followed by multiple doses on Days 8-12

Trial Locations (1)

21201

Pharmaron, Baltimore

All Listed Sponsors
lead

Yiling Pharmaceutical Inc.

INDUSTRY

NCT05223660 - A Phase I Pharmacokinetics Study for KT07 Capsule | Biotech Hunter | Biotech Hunter